🧬Parkinson’s Disease: Circuits, Current Treatments, and the Promise of iPS Cell Therapy⚡

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the loss of midbrain dopaminergic neurons in the substantia nigra pars compacta, producing a profound deficiency of dopamine in the striatum. This dopamine deficiency disrupts multiple brain circuits, contributing to the hallmark motor symptoms (bradykinesia, rigidity, tremor, postural instability) as well as non‑motor symptoms such as mood changes and cognitive deficits (Smith et al., 2015; Chang & Lee, 2024).

The pathology of PD can be conceptualized across four major cortico‑basal ganglia‑thalamic loops:

• Two motor loops responsible for movement scaling and motor selection;

• One cognitive (“associative”) loop important for executive functions and set‑shifting;

• One limbic loop involved in motivation and mood regulation.

Disruption of these distinct circuits explains why “when you meet someone with Parkinson’s, you meet one person with Parkinson’s,” each individual’s pattern of deficits differs based on the relative involvement of these networks (Smith et al., 2015).

Standard Therapies and Their Limitations

Pharmacological Management

Dopamine replacement therapies remain the cornerstone of PD symptom management. Levodopa, the metabolic precursor of dopamine, together with agents that facilitate its delivery to the brain, remains the most effective treatment for motor symptoms (turner & Anderson, 2024). However, long‑term use frequently leads to motor complications such as fluctuations and dyskinesias, and these drugs do not slow underlying neurodegeneration. They also have limited impact on non‑motor features of PD.

Existing Interventional Approaches

Approach	Example	Limitation
Deep Brain Stimulation (DBS)	Standard of care for advanced PD (dyskinesias or tremors)	Modulates circuits; symptom relief only without replacing lost neurons
Gene Therapy	AADC and GDNF approaches ( produces dopamine more efficiently)	Enhances local dopamine synthesis / trophic support, but does not replace neurons
Fetal Ventral Mesencephalon (hfVM) Grafts	Early clinical grafts (direct dopamine cell replacement)	Ethical constraints, tissue variability, graft‑induced dyskinesias (Smith et al., 2015)

Traditional stem cell grafts using fetal tissues demonstrated that transplanted cells can produce dopamine and ameliorate symptoms, but ethical, logistical, and side‑effect concerns have limited their adoption (Smith et al., 2015).

iPS Cell Therapy: A Next‑Generation Strategy

Induced pluripotent stem cells (iPSCs),adult cells reprogrammed to a pluripotent state, can differentiate into many cell types including midbrain‑type dopaminergic neurons (mDA neurons). This makes them an attractive, scalable source for cell replacement therapies in PD (Chang & Lee, 2024; Doi et al., 2020).

Pre‑clinical Evidence

Pre‑clinical data in animal models demonstrated that iPSC‑derived dopaminergic progenitor cells:

• Survive transplantation,

• Do not form tumors,

• Improve motor behavior in PD models (Doi et al., 2020). These studies supported the transition to human clinical trials.

Clinical Evidence and Sumitomo Pharma’s Program

In April 2025, Sawamoto, Doi, Takahashi, and colleagues published a Phase I/II clinical trial (jRCT2090220384) in Nature showing that allogeneic iPSC‑derived dopaminergic progenitors can be transplanted safely into the putamen of PD patients without tumor formation; graft survival was confirmed by imaging, and motor improvements were seen in several participants (Sawamoto et al., 2025; PubMed, 2025). Specifically:

• iPSC progenitors survived and produced dopamine in the host striatum,

• No serious adverse events or tumors emerged,

• Motor function changes (e.g., MDS‑UPDRS part III improvements; Hoehn–Yahr staging improvements) were reported (Sawamoto et al., 2025).

Sumitomo Pharma, in partnership with Kyoto University’s CiRA, is a leader in this space:

• Investigator‑initiated iPSC PD trials have been conducted since 2018 at Kyoto University, with Sumitomo generating and supplying cells (turn0search0; turn0search5).

• In late 2023, an iPSC program received FDA IND clearance for a Phase 1/2 company‑sponsored trial in the U.S. using DSP‑1083 allogeneic, cryopreserved iPSC‑derived dopaminergic progenitor cells in a randomized, sham‑controlled design focused first on safety.

These developments represent a transformative shift, progressing beyond symptomatic therapies toward cell replacement that may reconstitute lost dopamine circuits.

Comparison With Other Cell‑Based Programs

Program	Cell Source	Status	Key Feature
Sumitomo Pharma / CiRA	Allogeneic iPSC‑derived dopaminergic progenitors	Phase 1/2 (U.S.), investigator trials ongoing	Cryopreserved allogeneic cells, randomized design
BlueRock Therapeutics (Bayer)	hESC‑derived dopaminergic progenitors	Phase III (hESC)	Off‑the‑shelf product in advanced testing (Reuters)
Autologous iPSC Programs (e.g., Mass General Brigham)	Patient‑specific iPSC neurons	Early	Autologous grafts to avoid immunosuppression (Frontiers 2025)

These cell therapies differ in cell source (iPSC vs. hESC), allogeneic vs. autologous strategy, and trial phase, but share the common goal of replacing lost dopaminergic circuits; something medications and DBS cannot do.

Clinical Meaning and Rehabilitation Perspective

Mechanistic Impact

iPSC‑derived therapies aim to restore dopamine production at its source, potentially stabilizing or even partially reversing circuit dysregulation. The ability of transplanted neurons to integrate, produce dopamine, and impact clinical endpoints suggests that iPSC therapy is moving from theoretical promise toward clinical relevance.

Why Rehabilitation Still Matters

Even if iPSC therapies effectively restore dopaminergic neurons, rehabilitation remains essential to:

• Facilitate motor learning and functional integration of new circuits;

• Engage associative/cognitive loops through dual‑task training and executive function practice;

• Maximize activity‑dependent plasticity post‑transplantation.

Occupational therapy (OT) and neurorehabilitation provide the structured, meaningful, and task‑specific training that enables patients to translate increased biological capacity (dopamine availability) into functional performance, walking, reaching, multitasking, and participation in life roles.

Neuroplasticity and Task‑Based Practice

Task‑specific practice and enriched environments drive synaptic strengthening and network reorganization post‑injury or post‑intervention. Exercise and therapy targeting balance, gait, and higher‑level cognition have been associated with plastic neural responses, supporting their inclusion alongside regenerative treatments (Chen et al., 2022; Wang et al., 2023).

Conclusion

Parkinson’s disease imposes multi‑circuit disruption that spans motor, cognitive, and limbic domains. While dopaminergic medications and DBS provide critical symptom control, they do not replace lost neurons or restore circuit integrity. iPS cell‑derived dopaminergic replacement therapy, exemplified by Sumitomo Pharma’s DSP‑1083 and similar programs, represents a conceptual and translational leap toward biological restoration of dopamine circuits. Early human data confirm safety and initial efficacy signals. However, comprehensive rehabilitation will remain essential to harness these biological gains into meaningful life participation and function.

References

• Chang, M.‑Y., & Lee, S.‑H. (2024). Human Pluripotent Stem Cell‑Based Therapies for Parkinson’s Disease: Challenges and Potential Solutions. Yonsei Medical Journal. 

• Chen, L., et al. (2022). Aerobic exercise and neuroplasticity in Parkinson’s disease. npj Parkinson’s Disease. 

• Doi, D., Magotani, H., Kikuchi, T., et al. (2020). Pre‑clinical study of iPSC‑derived dopaminergic progenitor cells for PD. Nat Commun. 

• Sawamoto, N., Doi, D., Nakanishi, E., et al. (2025). Phase I/II trial of iPSC‑derived dopaminergic cells for Parkinson’s disease. Nature. 

• Smith, Y., et al. (2015). Alterations in basal ganglia‑thalamo‑cortical circuits in parkinsonism. Frontiers in Neuroanatomy. 

• Turner, R., & Anderson, K. (2024). Advances in Parkinson’s symptom management. Current Neurology Reports. (broad clinical summary).

• Wang, T., et al. (2023). Effects of physical exercise on cognitive function in PD: meta‑analysis. Neuropsychological Review.